Trial · NCT02701608
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
NCT02701608, Phase 3, Completed, University Hospital, Tours
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus. Trials, record NCT02701608. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02701608
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
- NCT number
- NCT02701608
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 162 participants, actual
- Lead sponsor
- University Hospital, Tours
- Conditions
- Infective Endocarditis
- Interventions
- Levofloxacin, Rifampicin, Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
- First posted
- 2016-03-08
- Last updated
- 2026-02-12
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment failure | up to 3 months after the end of antibiotic treatment | Failure is a composite outcome defined by death from all causes and/or symptomatic embolic events and/or unplanned valvular surgery and/or a microbiological relapse (with the primary pathogen). |
| Secondary | death from all-cause | up to 6 months after the end of antibiotic treatment | death from all-cause |
| Secondary | number of symptomatic embolic events | up to 6 months after the end of antibiotic treatment | secondary osteo-articular, splenic or brain localization |
| Secondary | unplanned valvular surgery | up to 6 months after the end of antibiotic treatment | unplanned valvular surgery |
| Secondary | relapse of positive blood cultures | up to 6 months after the end of antibiotic treatment | relapse of positive blood cultures with the primary pathogen |
| Secondary | microbiological relapse with a different pathogen from the primary pathogen | up to 6 months after the end of antibiotic treatment | Relapse of positive blood cultures with a different pathogen within 3 months after the end of antibiotic therapy |
| Secondary | Echocardiography | up to 6 months after the end of antibiotic treatment | An apparition, an increase or decrease of the following items: vegetation, abscess, perforation, fistula, dehiscence of a prosthetic valve, will be searched at each ultrasound examination at : the end of antibiotic treatment, at 3 months and 6 months after the end of antibiotic treatment |
| Secondary | Catheter related adverse events | up to 6 months after the end of antibiotic treatment | Catheter-related AE: infectious (e.g. catheter-related bacteraemia) or non-infectious catheter-related complications (e.g. extravasation). |
| Secondary | other healthcare-acquired infections | up to 6 months after the end of antibiotic treatment | other healthcare-acquired infections, including urinary tract infections, pneumonia, surgical site infection, Clostridium difficile infections |
| Secondary | Number of participants with an antibiotic modification | up to the end of antibiotic treatment | All change regarding antibiotic treatment administered will be recorded (drug, dose or duration) |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32665381 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02701608
GET https://conductscience.org/api/trials/v1/NCT02701608/registered